A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION

Similar documents
The New Kidney Allocation System: What You Need to Know. Anup Patel, MD Clinical Director Renal and Pancreas Transplant Division Barnabas Health

Blood Group Incompatible Renal Transplantation and Apheresis. Liz Wright Clinical Nurse Specialist Great Ormond Street Hospital NHS FT

Transplant Update New Kidney Allocation System Transplant Referral Strategies. Antonia Harford, MD University of New Mexico

Solid Organ Transplant

A 2 /A 2 B to B Renal Transplantation: Past, Present, and Future Directions

The Kidney Allocation System Changed in a Substantive Way on December 5, Your Patients Have Been, and Will Be, Affected by These Changes

Renal Transplantation: Allocation challenges and changes. Renal Transplantation. The Numbers 1/13/2014

Transplant Applications of Solid phase Immunoassays Anti HLA antibody testing in solid organ transplantation

Transplant in Pediatric Heart Failure

Transfusion support in Transplantation

Strategies for Desensitization

APHERESIS FOR DESENSITIZATION OF NON-RENAL TRANSPLANTS

ABO. ABO ABO ABO ABO ABO ABO ABO ABO. Key words ABO. Alexandre ABO ABO. double filtration plasmapheresis, DFPP. antibody-mediated rejection, AMR

IMMUNOBIOLOGY OF TRANSPLANTATION. Wasim Dar

Analysis of the Results of ABO-Incompatible Kidney Transplantation: In Comparison with ABO-Compatible Kidney Transplantation

Guidance for ABO Subtyping Organ Donors for Blood Groups A and AB

Transfusion and Apheresis Science

U.S. changes in Kidney Allocation

Diagnosis and Management of Acute and Chronic Humoral Rejection. Lars Pape

UEMS & EBS: DIVISION OF TRANSPLANT SURGERY

A Guide to Better Living

Living-donor kidney transplantation across ABO barriers: the first case in Thailand

The New Kidney Allocation System (KAS) Frequently Asked Questions

Patient Education Transplant Services. Glossary of Terms. For a kidney/pancreas transplant

Living Kidney Donation. Dr. Joseph Keith Melancon

Answers to Your Questions about a Change in Kidney Allocation Policy What you need to know

Living Donor Paired Exchange (LDPE)

ABO INCOMPATILIBITY AND TRANSPLANTATION

Supporting solid organ transplants: Challenges for Blood Transfusion Labs

Desensitization for solid organ and hematopoietic stem cell transplantation

Update on Kidney Allocation

Desensitization in Kidney Transplant. James Cooper, MD Assistant Professor, Kidney and Pancreas Transplant Program, Renal Division, UC Denver

2017 BANFF-SCT Joint Scientific Meeting. BARCELONA March 2017

FAQs about upcoming OPTN policy changes related to blood type determination, reporting, and verification.

EBV Protocol

ABO mismatched Renal Transplants

AGENDA Region 3 Meeting Hilton Garden Inn Atlanta Airport/Millenium Center 2301 Sullivan Rd College Park, GA August 25, 2017

To watch a videotaped interview with this patient, visit clevelandclinic.org/transplant. clevelandclinic.org/transplant

ABO Antibody Titer and Risk of Antibody-Mediated Rejection in ABO-Incompatible Renal Transplantation

ABO-incompatible kidney transplantation in elderly patients over 60 years of age

Post-Transplant Monitoring for the Development of Anti-Donor HLA Antibodies

UW MEDICINE PATIENT EDUCATION. Kidney Transplant. A treatment option for kidney disease. Kidney Transplant

KIDNEY TRANSPLANTATION: THE BIG PICTURE

Five papers that influenced my practice. Stephen Marks Consultant Paediatric Nephrologist

Simultaneous Pancreas Kidney Transplantation:

Kidney Transplant Activity New Zealand

Figure 1. Actuarial survival of patients with ABO I, ABO compatible, and ABO identical grafts.

Kidney Transplant Activity New Zealand

Paired Donation. Andrew Bradley Rachel Johnson Joanne Allen Susan V Fuggle. Cambridge University NHS Hospitals NHS Foundation trust

Pancreas After Islet Transplantation: A First Report of the International Pancreas Transplant Registry

Lessons Learned from ABO-Incompatible Living Donor Kidney Transplantation : 20 Years Later

Posttransplant Human Leukocyte Antigen Antibodies in Stable Kidney Transplant Recipients

Pulmonary AMR Therapeutic Options & Strategies: The Old and the New. Ramsey Hachem, MD March 28, 2017

Kidney Transplant. Patient Education. A treatment option for kidney disease. Overview. Kidney Early Education Program (KEEP) Chapter 5

Live Donor Liver Transplantation: A Life Saving Option for End Stage Liver Disease

Review of Rituximab and renal transplantation. Dr.E Nemati. Professor of Nephrology

Chapter 7. Australian Waiting List. ANZDATA Registry 39th Annual Report. Data to 31-Dec-2015

Why so Sensitive? Desensitizing Protocols for Living Donor Kidney Transplantation

6/19/2012. Who is in the room today? What is your level of understanding of Donor Antigens and Candidate Unacceptables in KPD?

Immunohaematology: a branch of immunology that deals with the immunologic properties of blood.

3/6/2017. Prevention of Complement Activation and Antibody Development: Results from the Duet Trial

The Lecture s topics

Clinical Questions of Combined Liver Kidney Transplantation

FAIRNESS/EQUITY UTILITY/EFFICACY EFFICIENCY. The new kidney allocation system (KAS) what has it done? 9/26/2018. Disclosures

Is it safe to transplant against HLA DSA in cardiothoracic patients? development and implementation of national Guidelines

Questions and Answers for Transplant Candidates about the Kidney Allocation System

Transplantation in Australia and New Zealand

New Zealand Kidney Allocation Scheme

Three Sides to Allocation. ECD Extended Criteria Donor

Hong Kong Journal Nephrol of 2000;(2): Nephrology 2000;2(2): BR HAWKINS ORIGINAL A R T I C L E A point score system for allocating cadaver

HHS Public Access Author manuscript Kidney Int. Author manuscript; available in PMC 2015 September 01.

Are two better than one?

Oxford Transplant Centre. Live donor kidney transplantation what if we are not a match?

Apheresis: Clinical Indications

Treatment of Chronic Antibody Mediated Rejection

For more information about how to cite these materials visit

The New Kidney Allocation Policy: Implications for Your Patients and Your Practice

The new Banff vision of the role of HLA antibodies in organ transplantation: Improving diagnostic system and design of clinical trials

Feasible usage of ABO incompatible grafts in living donor liver transplantation

New Ways to Tackle a Growing Health Care Dilemma - ESRD

Serum samples from recipients were obtained within 48 hours before transplantation. Pre-transplant

Should red cells be matched for transfusions to patients listed for renal transplantation?

Single-Center Kidney Paired Donation: The Methodist San Antonio Experience

Disparities in Transplantation Caution: Life is not fair.

10:15-10:35 Welcome and update from Regional Councillor Lewis Teperman, MD Northwell Health Region 9 Councillor

Should Pediatric Patients Wait for HLA-DR-Matched Renal Transplants?

Allocation of deceased donor kidneys. Phil Clayton NSW Renal Group 14 June 2012

Virtual Crossmatch in Kidney Transplantation

AND My presentation does include discussion of off-label or investigational use (empiric therapy)

Organ Procurement and Transplantation Network

Le migliori strategie immunosoppressive per il paziente con re-trapianto Prof. Maurizio Salvadori FIRENZE

Kidney Allocation- Will it ever be fair? Peter G Stock MD, PhD UCSF Department of Surgery. Would you accept this offer?

OPTN/UNOS Pediatrics Transplantation Committee Report to the Board of Directors December 1-2, 2015 Richmond, Virginia

Takashi Yagisawa 1,2*, Makiko Mieno 1,3, Norio Yoshimura 1,4, Kenji Yuzawa 1,5 and Shiro Takahara 1,6

All you wanted to know about transfusion support for transplants

Increased Access to Transplantation for Blood Group B Cadaveric Waiting List Candidates by Using A 2 Kidneys: Time for a New National System?

23/10/2017. Panel Reactive Antibodies and Crossmatch by Flow Cytometry. Antibodies against. Renal transplantation. Antibody mediated rejection (AMR)

Transcription:

THE NEW KIDNEY ALLOCATION SYSTEM: A POTENTIAL EXPANSION OF THERAPEUTIC APHERESIS UTILIZATION Paul Warner, PhD, D(ABHI) Director, HLA/Immunogenetics Laboratory Bloodworks Northwest Seattle, Washington

Disclosure I have nothing to disclose that is relevant to this presentation

Outline History of ABO-i Renal Transplantation Early experience Minor vs. Major incompatibility National Minor ABOi Allocation Old vs. new system Unresolved Issues

History of ABO-i Renal Txp. 1955: Experiences with Renal Homotransplantation in the Human: Report of Nine Cases Hume, et al, J Clin Invest One case of ABO-I (Donor B Recipient O) we do not feel that renal transplantation in the presence of blood incompatibility is wise, if only on the basis of possible local damage to the kidney. Very few ABO-I transplants done until 1970s

History of ABO-i Renal Txp. 1970s: Minor ABO-i renal txp (A2 O and B) became more common Low initial titers necessary (1:4) Poor outcomes led to abandonment of practice in 1980s

A1 A2

History of ABO-i Renal Txp. 1980: Accidental A O transplant, used plasmapheresis to reverse rejection/damage Slapak, et al, Transplantation, 1981, 31; 4-7 Immediate reversal of intrarenal vascular coagulation Despite an anti-a antibody rebound weeks after transplantation, graft biopsies were negative for intravascular coagulation (Accommodation)

Accommodation Absence of allograft injury in the presence of donor-specific antibodies Evidence: Protocol biopsies 6-12 months post transplant are C4d-positive Setoguchi et al, Am J Transplant 2008;8:86-94 Proposed mechanisms Up-regulation of natural complement inhibitors in non-human primate model (Chen et al, Am J Transplant 2011; 11:2057-2066) Upregulation of anti-inflammatory/anti-apoptotic genes (Bach et al, Nature Med 1997; 3: 196-204)

Accommodation Contd Accommodation may be the body s natural balancing act (immune-related injury vs. infection ) In ABOi renal transplantation, keeping the titers low is critical the first few weeks post-tx Long term, down-regulation of A/B antigens may contribute Tanabe et al, Transpl Immunol 2011; 25: 1-6

A2/A2B-to-B Allocation System Midwest Transplant Network Bryan, et al American Journal of Transplantation 2015, xx, 1-10 Designed to increase access for ABO-B recipients on deceased donor wait list

A2/A2B-to-B Allocation System Midwest Transplant Network Bryan, et al American Journal of Transplantation 2015, xx, 1-10 2001-2013: ABO-B candidates received 10% more kidney transplants than previous period Transplant rates for ABO-B candidates 11.9% (1989-2001) 13% (2001-2013) Composition of waitlist: 16% ABO-B Candidates

MTN Early Principles Pre-Transplant Anti-A Titers Matter 14/14 pts w/ anti-a titers < 8 had 100% early and long term graft function 6/11 pts w/ anti-a titers 8 lost function at 1 month, and most never regained Standard Immunosuppression Is Sufficient No apheresis, splenectomy, IVIg As long as anti-a titers are < 8

MTN Early Principles Anti-A titers are relatively stable, and usually low Test every three months No need for immediate pre-transplant testing 80%-90% of ABO-B candidates have consistently low anti-a titers

MTN Early Principles ABO-B candidates rarely have total titers (IgG and IgM) higher than IgG-only titers DTT-treated serum, using a tube titration method, became the norm (UNOS Method) IgM antibodies may be clinically-relevant Tierney, et al, Clin Transpl., 2015

December 2014: New KAS Old: Anti-A titers performed with UNOS titration method New: Centers may use whatever titration method they choose Old: Titers were mandated to be performed every 3 months New: Regular titer measurements are optional Old: Candidates with titers >4 were automatically ineligible New: Centers may transplant regardless of titer values

Unresolved Issues Differential Antigen Expression

Unresolved Issues Differential Antigen Expression A2-transferase Kidney

Unresolved Issues Which Titer method? (Masterson, et al,

Unresolved Issues Why aren t post-transplant anti-a titers monitored?? At least for the first few weeks Very few studies

Unresolved Issues Different Apheresis Methods

Summary Minor ABOi renal transplant have outcomes similar to ABOc transplants Provided initial titers are low Centers now have the option to employ TA for candidates that have titers > 4 Useful for highly HLA-sensitized recipients Post-transplant titer monitoring may be useful Employ TA if titers increase

Thank You! Questions?